FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHA	NGES IN BENEFIC	IAL OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* CHAMPSI FARAH																			erson(s) to I	
(Last) (First) (Middle) ONE EMBARCADERO CENTER, 37TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 10/23/2013										Office below	cer (give title ow)		Other (specify below)	
(Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,				es Acquired (A) o Of (D) (Instr. 3, 4 a			and 5) Securi Benefi		ies cially Following	Forn (D) o	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	() (I	A) or D)	Price		Transa	nsaction(s) str. 3 and 4)			(111341. 4)
Common Stock 10/23/20						2013		S		447,499(1)	D	\$15.51		1,714,330			I	See footnote ⁽²⁾	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative ecurity nstr. 3) Conversion or Exercise (Month/Day/Year) Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)			saction le (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		nstr. 3 nount mber	t		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. Shares sold to the underwriters in connection with the sale of Common Stock by Ms. Champsi as follows: 409,872 shares sold by Alta Biopharma Partners III, L.P.; 27,526 shares sold by Alta Biopharma Partners III GmbH & Co. Beteiligungs KG; and 10,101 shares sold by Alta Embarcadero Biopharma Partners III, LLC.
- 2. Securities held by Alta Biopharma Partners III, L.P., Alta Biopharma Partners III GmbH & Co. Beteiligungs KG and Alta Embarcadero Biopharma Partners III, LLC (collectively, the "Alta Funds"). The directors of Alta Biopharma Management III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a general partner of Alta Biopharma Partners III, LLC, which is a ge Management III, LLC and a manager of Alta Embarcadero Biopharma Partners III, LLC, may be deemed to beneficially own the securities. Ms. Champsi disclaims beneficial ownership over these securities, except to the extent of her pecuniary interest therein.

/s/ Farah Champsi 10/23/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.